Biofrontera Inc. BFRI
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Biofrontera Inc. (BFRI) is a healthcare company listed in the US with a market value of about $10M. In the twelve months to September 30, 2026 it had revenue of $48M and net income of -$6M, a net margin of -12.7%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is financial health (0/5).
Key numbers: 5-year revenue growth of 17% a year, a 5-year average ROIC of -117%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 222% above the current price.
About Biofrontera
Biofrontera is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $19M in 2020 to $42M in 2025, growth of about 17.2% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 862% over three years (dilution for shareholders). It spends 9% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $48M | $42M | $37M | $34M | $29M | $24M | $19M |
| Net income | -$6M | -$11M | -$18M | -$20M | -$640000 | -$38M | -$11M |
| Free cash flow | -$6M | -$13M | -$10M | -$25M | -$16M | -$27M | — |
| EPS (diluted) | $-0.43 | $-1.04 | $-3.22 | $-13.02 | $-0.61 | $-85.60 | $-9589.60 |
| Net margin | -12.7% | -25.3% | -47.6% | -59.1% | -2.2% | -156.5% | -58.3% |
| ROIC | — | -53.9% | -145.3% | -175.8% | -58.2% | -151.5% | -130.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $3.00, 329% above the current price; targets range from $3.00 to $3.00; the consensus rating is “Strong buy”; expected EPS is $-0.18 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Biofrontera stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 222% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Biofrontera pay a dividend?
Not currently.
Is Biofrontera a good stock to buy?
We do not give buy or sell advice. Biofrontera scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.